Skip to main content

Advertisement

Log in

Severe aplastic anemia in a patient with erythropoietic protoporphyria successfully treated by avatrombopag

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

References

  1. Balwani M (2019) Erythropoietic protoporphyria and X-linked protoporphyria: pathophysiology, genetics, clinical manifestations, and management. Mol Genet Metab 128(3):298–303. https://doi.org/10.1016/j.ymgme.2019.01.020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Meerman L (2000) Erythropoietic protoporphyria. An overview with emphasis on the liver. Scand J Gastroenterol Suppl 232:79–85

    Google Scholar 

  3. Shirota T, Yamamoto H, Hayashi S et al (2000) Myelodysplastic syndrome terminating in erythropoietic protoporphyria after 15 years of aplastic anemia. Int J Hematol 72(1):44–47

    CAS  PubMed  Google Scholar 

  4. Casanova-González MJ, Trapero-Marugán M, Jones EA et al (2010) Liver disease and erythropoietic protoporphyria: a concise review. World J Gastroenterol 16(36):4526–4531. https://doi.org/10.3748/wjg.v16.i36.4526

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ardalan ZS, Chandran S, Vasudevan A et al (2019) Management of patients with erythropoietic protoporphyria-related progressive liver disease. Liver Transpl 25(11):1620–1633. https://doi.org/10.1002/lt.25632

  6. Bacigalupo A (2017) How I treat acquired aplastic anemia. Blood 129(11):1428–1436. https://doi.org/10.1182/blood-2016-08-693481

    Article  CAS  PubMed  Google Scholar 

  7. Gilreath J, Lo M, Bubalo J (2021) Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists. Drugs 81(11):1285–1305. https://doi.org/10.1007/s40265-021-01553-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Drexler B, Passweg J (2021) Current evidence and the emerging role of eltrombopag in severe aplastic anemia. Ther Adv Hematol 12:2040620721998126. https://doi.org/10.1177/2040620721998126

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank the families for giving consent to disclose their medical records and provide blood samples for our study.

Funding

The work was supported by the National Natural Science Foundation of China (NSFC) (81970106).

Author information

Authors and Affiliations

Authors

Contributions

Z.J. and M.C. provided diagnosis and treatment for the patient and wrote the manuscript. Both authors reviewed the manuscript and approved the final submission of the manuscript.

Corresponding author

Correspondence to Miao Chen.

Ethics declarations

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of interest

The authors declare no competing interests.

Informed consent

Informed consent was obtained from the patient included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, Z., Jiang, X. & Chen, M. Severe aplastic anemia in a patient with erythropoietic protoporphyria successfully treated by avatrombopag. Ann Hematol 101, 1361–1363 (2022). https://doi.org/10.1007/s00277-021-04726-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-021-04726-2

Navigation